ArticleInternational journal of experimental pathology2006
A preliminary in vitro study into the use of IL-1Ra gene therapy for the inhibition of intervertebral disc degeneration.
Article in International journal of experimental pathology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 2 syntheses or guidelines pooled it, 103 citations in OpenAlex.
- The role of single nucleotide polymorphisms ofF1000Research · 2021Pooled it
- Meta-analysis of the effects of genetic polymorphisms on intervertebral disc degeneration.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2017Pooled it
- Complex Mechanical Loading and Pro-Inflammatory Cytokines in Intervertebral Disc Degeneration.JOR spine · 2026Article
- PCRX-201, a novel IL-1Ra gene therapy treatment approach for low back pain resulting from intervertebral disc degeneration.Gene therapy · 2025Article
- Nucleus pulposus cell network modelling in the intervertebral disc.NPJ systems biology and applications · 2025Article
- Progress in regulating inflammatory biomaterials for intervertebral disc regeneration.Bioactive materials · 2024Review
- Role and molecular mechanism of ghrelin in degenerative musculoskeletal disorders.Journal of cellular and molecular medicine · 2023Review
- Cytokine Inhibitors Upregulate Extracellular Matrix Anabolism of Human Intervertebral Discs under Alginate Beads and Alginate-Embedded Explant Cultures.International journal of molecular sciences · 2023Article
- Human 3D nucleus pulposus microtissue model to evaluate the potential of pre-conditioned nasal chondrocytes for the repair of degenerated intervertebral disc.Frontiers in bioengineering and biotechnology · 2023Article
- Elucidating the Focal Immunomodulatory Clues Influencing Mesenchymal Stem Cells in the Milieu of Intervertebral Disc Degeneration.Current stem cell research & therapy · 2023Article
- Self-Assembling Peptide Hydrogels as Functional Tools to Tackle Intervertebral Disc Degeneration.Gels (Basel, Switzerland) · 2022Review
- Inhibition of toll-like receptor 4 protects against inflammation-induced mechanobiological alterations to intervertebral disc cells.European cells & materials · 2021Article
- Bone Morphogenetic Proteins for Nucleus Pulposus Regeneration.International journal of molecular sciences · 2020Article
- Stem cell therapy in discogenic back pain.Journal of spine surgery (Hong Kong) · 2019Review
- Therapeutic potential of growth differentiation factors in the treatment of degenerative disc diseases.JOR spine · 2019Review
- MicroRNA-221 silencing attenuates the degenerated phenotype of intervertebral disc cells.Aging · 2018Article
- Understanding the molecular biology of intervertebral disc degeneration and potential gene therapy strategies for regeneration: a review.Gene therapy · 2018Review
- Novel therapeutic strategies for degenerative disc disease: Review of cell biology and intervertebral disc cell therapy.SAGE open medicine · 2018Review
- Ghrelin protects against nucleus pulposus degeneration through inhibition of NF-κB signaling pathway and activation of Akt signaling pathway.Oncotarget · 2017Article
- Current strategies for treatment of intervertebral disc degeneration: substitution and regeneration possibilities.Biomaterials research · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Conventional therapies for low back pain (LBP) are purely symptomatic and do not target the cause of LBP, which in approximately 40% of cases is caused by degeneration of the intervertebral disc (DIVD). Targeting therapies to inhibit the process of degeneration would be a potentially valuable treatment for LBP. There is increasing evidence for a role for IL-1 in DIVD. A natural inhibitor of IL-1 exists, IL-1Ra, which would be an ideal molecular target for inhibiting IL-1-mediated effects involved in DIVD and LBP. In this study, the feasibility of ex vivo gene transfer of IL-1Ra to the IVD was investigated. Monolayer and alginate cultures of normal and degenerate human intervertebral disc (IVD) cells were infected with an adenoviral vector carrying the IL-1Ra gene (Ad-IL-1Ra) and protein production measured using an enzyme-linked immunosorbent assay. The ability of these infected cells to inhibit the effects of IL-1 was also investigated. In addition, normal and degenerate IVD cells infected with Ad-IL-1Ra were injected into degenerate disc tissue explants and IL-1Ra production in these discs was assessed. This demonstrated that both nucleus pulposus and annulus fibrosus cells infected with Ad-IL-1Ra produced elevated levels of IL-1Ra for prolonged time periods, and these infected cells were resistant to IL-1. When the infected cells were injected into disc explants, IL-1Ra protein expression was increased which was maintained for 2 weeks of investigation. This in vitro study has shown that the use of ex vivo gene transfer to degenerate disc tissue is a feasible therapy for the inhibition of IL-1-mediated events during disc degeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.